CLINICAL ROLE -
Future Directions for the Treatment of CLL
Bhavesh Shah, RPh, BCOP, and Ryan Jacobs, MD, discuss emerging agents in the pipeline and the future treatment landscape for CLL.
Role of Pharmacists in the Management of CLL
Ryan Jacobs, MD, and Bhavesh Shah, RPh, BCOP, comment on the role of pharmacists in clinical practice for managing patients with CLL.
BTK Inhibitors: Switching Therapies in CLL
Key opinion leaders in hematology-oncology share recommendations on switching from first-generation BTK inhibitors to next-generation BTK inhibitors for the management of patients with CLL.
Phase 3 SEQUOIA Study: Zanubrutinib in Treatment-Naïve CLL
Dr Ryan Jacobs, MD, leads a review of the phase 3 SEQUOIA trial presented at ASH 2021 evaluating the use of zanubrutinib for previously untreated CLL and discusses the management of adverse events with BTK inhibitors.
Treatment Selection Among BTK Inhibitors for First-Line CLL Treatment
Ryan Jacobs, MD, and Bhavesh Shah, RPh, BCOP, provide insight on considerations when choosing a BTK inhibitor for initial treatment of chronic lymphocytic leukemia.
Goals of Therapy for CLL
Experts in hematology/oncology discuss goals of therapy and optimal treatment selection for patients with chronic lymphocytic leukemia.
Role of Chemotherapy in Frontline CLL Treatment
Dr Ryan Jacobs evaluates the use of chemotherapy options for first-line treatment of CLL.
Individualized Treatment Approach for the Management of CLL
Bhavesh Shah, RPh, BCOP, and Ryan Jacobs, MD, share considerations for approaching an individualized treatment regimen for patients with CLL.
2 Commerce Drive Cranbury, NJ 08512